Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1221-1230

  Eghbali Fatourechi, Guitty ^a   Khosla, Sundeep ^a   Sanyal, Arunik ^a   Boyle, William J ^b,c   Lacey, David L ^b   Riggs, B Lawrence ^a  

^a MAYO CLINIC   (United States)

^b AMGEN INC   (United States)

^c Protein Pathways Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; ESTROGEN RECEPTOR; LIGAND;

ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; ESTROGEN DEFICIENCY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MENOPAUSAL SYNDROME; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STROMA CELL;

ADULT; APOPTOSIS REGULATORY PROTEINS; BONE RESORPTION; CARRIER PROTEINS; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037398261     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317215     Document Type: Article

References (47)

1. Riggs, B.L., Khosla, S., and Melton, L.J. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302.
2. Khosla, S., Melton, L.J., and Riggs, B.L. 2002. Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87:1443-1450.
3. Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137.
4. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of post-menopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051.
5. Tanaka, S., et al. 1993. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263.
6. Cenci, S., et al. 2000. Estrogen-deficiency induces bone loss by enhancing T-cell production of TNF-α. J. Clin. Invest. 106:1229-1327.
7. Lam, J., et al. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488.
8. Oursler, M.J., et al. 1991. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology. 129:3313-3320.
9. Hughes, D.E., et al. 1999. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2:1132-1136.
10. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345-357.
11. Hofbauet, L.C., et al. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:2-12.
12. Khosla, S. 2001. Minireview: The OPG/RANKL/RANK system. Endocrinology. 142:5050-5055.
13. Yasuda, H., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95:3597-3602.
14. Kanematsu, M., et al. 2000. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kB ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15:1321-1329.
15. Hofbauer, L.C., et al. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140:4367-4370.
16. Saika, M., Inoue, D., Kido, S., and Matsumoto, T. 2001. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen recepror-α. Endocrinology. 142:2205-2212.
17. Khosla, S., Atkinson, E.J., Dunstan, C.R., and O'Fallon, W.M. 2002. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J. Clin. Endocrinol. Metab. 87:1550-1554.
18. Shevde, N.K., Bendixen, A.C., Dienger, K.M., and Pike, J.W. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism c-jun repression. Proc. Natl. Acad. Sci. U. S. A. 97:7829-7834.
19. Simonet, W.S., et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309-319.
20. Lacey, D.L., et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165-176.
21. Gori, F., Thomas, T., Hicok, K.C., Spelsberg, T.C., and Riggs, B.L. 1999. Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J. Bone Miner. Res. 14:1522-1535.
22. Bodine, P.V.N., Trailsmirh, M., and Komm, B.S. 1996. Development and characterization of a conditionally transformed adult human osteoblastic cell line. J. Bone Miner Res. 11:806-819.
23. Locklin, R.M., et al. 2001. Assessment of gene regulation by bone morphogeneric protein 2 in human marrow stromal cells using gene array technology. J. Bone Miner Res. 16:2192-2204.
24. Khosla, S., et al. 2002. Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 13:394-399.
25. Gori, F., et al. 2000. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 141:4768-4776.
26. Gronthos, S., Graves, S.E., Ohta, S., and Simmons, P.J. 1994. The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood. 84:4164-4173.
27. Stewart, K., et al. 1999. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14:1345-1356.
28. Naeim, F. 1998. Pathology of bone marrow. 2nd edition. Williams & Wilkins. Baltimore, Maryland, USA. 61 pp.
29. Emery,J.G., et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:14363-14367.
30. Truneh, A., et al. 2000. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275:23319-23325.
31. Couse, J.F., and Kotach, K.S. 1999. Estrogen receptor null mice: what have we learned and where will they lead us. Endocr. Rev. 20:358-417.
32. Smith, E.P., et al. 1994. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med 331:1056-1061.
33. 3 or parathyroid hormone. J. Biol. Chem. 274:19301-19308.
34. Hofbauer, L.C., et al. 1999. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:255-259.
35. Owen, M., and Friedenstein, A.J. 1988. Stromal stem cells: marrowderived osteogenic precursors. Ciba Found. Symp. 136:42-60.
36. Kassem, M., Risteli, L., Mosekilde, L., Melsen, F., and Eriksen, E.F. 1991. Formation of osteoblast-like cells from human mononuclear bone marrow cultures. APMIS. 99:269-274.
37. Knapp, W. 1989. Leucocytes typing IV: white cell differentiation antigens. Oxford University Press. New York, New York, USA. 1182 pp.
38. Walczak, H., and Krammer, P.H. 2000. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256:58-66.
39. Atkins, G.J., et al. 2000. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone. 31:448-456.
40. Sedger, L.M., et al. 2002. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J. Immunol. 32:2246-2254.
41. Masuzawa, T., et al. 1994. Estrogen-deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 94:1090-1097.
42. Everts, V., et al. 2002. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J. Bone Miner. Res. 17:77-90.
43. Parfitt, A.M. 2001. The bone remodeling compartment: a circulatory function for bone lining cells. J. Bone Miner. Res. 16:1583-1585.
44. Gregorio, G.B., et al. 2001. Attenuation of the self-renewal of transitamplifying osteoblast progenitors in the murine bone marrow by 17β-estradiol. J. Clin. Invest. 107:803-812.
45. Kong, Y.-Y., et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315-323.
46. Kong, Y.-Y., et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:304-309.
47. Yano, K., et al. 1999. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14:518-527.